Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Crossroads in GDNF therapy for Parkinson's disease.
Sherer TB, Fiske BK, Svendsen CN, Lang AE, Langston JW. Sherer TB, et al. Among authors: langston jw. Mov Disord. 2006 Feb;21(2):136-41. doi: 10.1002/mds.20861. Mov Disord. 2006. PMID: 16470786
Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance.
San Luciano M, Tanner CM, Meng C, Marras C, Goldman SM, Lang AE, Tolosa E, Schüle B, Langston JW, Brice A, Corvol JC, Goldwurm S, Klein C, Brockman S, Berg D, Brockmann K, Ferreira JJ, Tazir M, Mellick GD, Sue CM, Hasegawa K, Tan EK, Bressman S, Saunders-Pullman R; Michael J. Fox Foundation LRRK2 Cohort Consortium. San Luciano M, et al. Among authors: langston jw. Mov Disord. 2020 Oct;35(10):1755-1764. doi: 10.1002/mds.28189. Epub 2020 Jul 14. Mov Disord. 2020. PMID: 32662532 Free PMC article.
Parkinson's disease is ready for precision medicine.
Sherer TB, Frasier MA, Langston JW, Fiske BK. Sherer TB, et al. Among authors: langston jw. Per Med. 2016 Sep;13(5):405-407. doi: 10.2217/pme-2016-0052. Epub 2016 Aug 9. Per Med. 2016. PMID: 29767601 No abstract available.
Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease.
Lai D, Alipanahi B, Fontanillas P, Schwantes-An TH, Aasly J, Alcalay RN, Beecham GW, Berg D, Bressman S, Brice A, Brockman K, Clark L, Cookson M, Das S, Van Deerlin V, Follett J, Farrer MJ, Trinh J, Gasser T, Goldwurm S, Gustavsson E, Klein C, Lang AE, Langston JW, Latourelle J, Lynch T, Marder K, Marras C, Martin ER, McLean CY, Mejia-Santana H, Molho E, Myers RH, Nuytemans K, Ozelius L, Payami H, Raymond D, Rogaeva E, Rogers MP, Ross OA, Samii A, Saunders-Pullman R, Schüle B, Schulte C, Scott WK, Tanner C, Tolosa E, Tomkins JE, Vilas D, Trojanowski JQ; 23andMe Research Team; Uitti R, Vance JM, Visanji NP, Wszolek ZK, Zabetian CP, Mirelman A, Giladi N, Orr Urtreger A, Cannon P, Fiske B, Foroud T. Lai D, et al. Among authors: langston jw. Ann Neurol. 2021 Jul;90(1):76-88. doi: 10.1002/ana.26094. Epub 2021 May 17. Ann Neurol. 2021. PMID: 33938021 Free PMC article.
GDNF in treatment of Parkinson's disease: response to editorial.
Lang AE, Langston JW, Stoessl AJ, Brodsky M, Brooks DJ, Dhawan V, Elias WJ, Lozano AM, Moro E, Nutt JG, Stacy M, Turner D, Wooten GF. Lang AE, et al. Among authors: langston jw. Lancet Neurol. 2006 Mar;5(3):200-2. doi: 10.1016/S1474-4422(06)70359-3. Lancet Neurol. 2006. PMID: 16488373 No abstract available.
Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.
Kalia LV, Lang AE, Hazrati LN, Fujioka S, Wszolek ZK, Dickson DW, Ross OA, Van Deerlin VM, Trojanowski JQ, Hurtig HI, Alcalay RN, Marder KS, Clark LN, Gaig C, Tolosa E, Ruiz-Martínez J, Marti-Masso JF, Ferrer I, López de Munain A, Goldman SM, Schüle B, Langston JW, Aasly JO, Giordana MT, Bonifati V, Puschmann A, Canesi M, Pezzoli G, Maues De Paula A, Hasegawa K, Duyckaerts C, Brice A, Stoessl AJ, Marras C. Kalia LV, et al. Among authors: langston jw. JAMA Neurol. 2015 Jan;72(1):100-5. doi: 10.1001/jamaneurol.2014.2704. JAMA Neurol. 2015. PMID: 25401511 Free PMC article.
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A; Parkinson Study Group. Shoulson I, et al. Among authors: langston jw. Ann Neurol. 2002 May;51(5):604-12. doi: 10.1002/ana.10191. Ann Neurol. 2002. PMID: 12112107 Clinical Trial.
Genetic modification of the association of paraquat and Parkinson's disease.
Goldman SM, Kamel F, Ross GW, Bhudhikanok GS, Hoppin JA, Korell M, Marras C, Meng C, Umbach DM, Kasten M, Chade AR, Comyns K, Richards MB, Sandler DP, Blair A, Langston JW, Tanner CM. Goldman SM, et al. Among authors: langston jw. Mov Disord. 2012 Nov;27(13):1652-8. doi: 10.1002/mds.25216. Epub 2012 Oct 8. Mov Disord. 2012. PMID: 23045187 Free PMC article.
353 results